Pharmacokinetics of L-dopa in patients with Parkinson's disease.
D001711:Biotransformation; D002230:Carbidopa / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D004295:Dihydroxyphenylalanine / Q000097:blood; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007700:Kinetics; D007980:Levodopa / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008750:Methyldopa / Q000097:blood; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects; D017448:Receptors, Dopamine D2; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use
D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D007980:Levodopa; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D002230:Carbidopa; D013976:Tiapamil Hydrochloride